ProvenCare对肺癌手术质量影响的初步评估
BACKGROUND: ProvenCare is a joint initiative of the American College of Surgeons Commission on Cancer, Geisinger, and The Society of Thoracic Surgeons (STS) to standardize evidence-based practices in the delivery of surgical lung cancer care.…
要点
- ProvenCare提高指南推荐的分期评估与纵隔分期率
- 30天死亡率与STS指标并发症无显著差异
- 多因素校正后围术期病残率与死亡率无显著差异
核心结论
- ProvenCare增加了指南推荐的术前评估流程使用,但短期手术结局无差异。
主要发现
- ProvenCare患者接受指南推荐分期评估和纵隔分期的比例更高(63.4% vs 49.4%,P < .001)。
- 30天死亡率无差异:肺叶切除1.4% vs 1.3%(P = .84),其他切除3.4% vs 2.0%(P = .054)。
- STS指标并发症无差异:肺叶切除10.8% vs 9.9%(P = .21),其他切除9.2% vs 9.4%(P = .92)。
- 校正患者因素后,围术期病残率和死亡率无显著差异(肺叶切除OR 1.07,95%CI 0.77-1.47;其他切除OR 0.97,95%CI 0.62-1.50)。
临床怎么用
- 可参考ProvenCare模式标准化肺癌术前评估流程,提高指南推荐的分期评估依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ProvenCare is a joint initiative of the American College of Surgeons Commission on Cancer, Geisinger, and The Society of Thoracic Surgeons (STS) to standardize evidence-based practices in the delivery of surgical lung cancer care. This study compares outcomes of ProvenCare patients with the STS Database. METHODS: Best practice elements were agreed on through expert consensus meetings. ProvenCare elements were used to direct care. Compliance was monitored while clinical outcomes were collected within the STS General Thoracic Surgery Database (GTSD). ProvenCare patient outcomes were compared with outcomes in all other STS GTSD patients. Univariable and multivariable logistic regression models compared morbidity and mortality. RESULTS: A total of 2026 patients at 23 ProvenCare hospitals were compared with 71 565 control patients at 311 hospitals from 2010 to 2016. ProvenCare patients were more likely to receive guideline-recommended staging evaluations and more likely to have mediastinal staging performed during resection (63.4% vs 49.4%; P < .001). There was no difference in 30-day mortality (1.4% vs 1.3% lobectomy [P = .84]; 3.4% vs 2.0% all other resections [P = .054]) or STS indicator complications (10.8% vs 9.9% lobectomy [P = .21]; 9.2% vs 9.4% all other resections [P = .92]). When controlling for patient-level clinical and demographic risk factors, the likelihood of perioperative morbidity and mortality was not significantly different (odds ratio [OR], 1.07 [95% CI, 0.77-1.47] lobectomy; OR, 0.97 [95% CI, 0.62-1.50] all other resections). CONCLUSIONS: Variability in preoperative evaluation of patients with lung cancer represents an opportunity to improve quality of care. ProvenCare increased use of guideline-recommended preoperative processes, which may improve cancer outcomes and survival, without resulting in differences in short-term surgical outcomes.
引用
- Facktor MA, Odell DD, Wood DE, et al. Initial Assessment of the Effect of ProvenCare on Lung Cancer Surgical Quality. Ann Thorac Surg. 2021. PMID: 34461073. doi:10.1016/j.athoracsur.2021.07.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。